Suven Pharmaceuticals Ltd - 543064 - Disclosure Of Related Party Transactions On A Consolidated Basis And Balances For The Half-Year Ended 30Th September, 2020
Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the half-year ended 30th September, 2020. Stock query: Suven Pharmaceuticals on short-term downtrend
A decline below 320 can pull the stock down to 295 and 280 over the short term
Suven Pharmaceuticals Q2 net profit declines 20% at Rs 74 crore
The company had posted a net profit of Rs 93 crore for the corresponding period of the previous fiscal, Suven Pharmaceuticals said in a filing to BSE.
Earnings Call for Q2FY21 of Suven Pharmaceuticals
Conference Call with Suven Pharma Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and half-year ended September 30, 2020. The advertisements as appeared on October 31, 2020 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q2 & H1FY21 Suven Pharma reports Q2 net profit decline of 20.35% to Rs 74.07 crore
Drug firm Suven Pharmaceuticals on Friday reported a 20.35 per cent decline in its consolidated net profit at Rs 74.07 crore for the quarter ended September 30, 2020. The company had posted a net profit of Rs 93 crore for the corresponding period of the previous fiscal, Suven Pharmaceuticals said in a filing to BSE. Consolidated total income of the company stood at Rs 237.74 crore for the quarter under consideration. It was Rs 278.37 crore for the same period year ago, it added. "The board has allotted the bonus shares at 1:1 ratio in its meeting held on September 29, 2020," the filing said. The board has approved capital expenditure (capex) plan of Rs 600 crore keeping in view of the proposed increase in capacity in Pashamylaram facility, replacement and modernization of production blocks in Suryapet facility, relocation of R&D facilities from Jeedimetla and acquisition of new technologies, it added. Shares of Suven Pharmaceuticals were trading at Rs 308.70 per scrip on BSE, down Suven Pharmaceuticals Ltd - 543064 - Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half-Year Ended 30Th September, 2020
With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. October 30, 2020, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and half-year ended 30th September, 2020. We are enclosing herewith the following documents: 1) Un-audited Standalone and Consolidated Financial Results for the quarter and half-year ended 30th September, 2020 2) Limited Review Reports on the financial results as mentioned above and 3) A copy of the News Release of our company We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 01:20 P.M. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Saturday, October 31, 2020 at 12:00 Noon IST to discuss the Un-audited Financial Results for the Q2 Financial Year 2021, to be declared on October 30, 2020. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation to our letter dated October 23, 2020 regarding to Notice of Board Meeting, please find enclosed the copies of the newspaper advertisements as appeared on October 24, 2020 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements